SecBot SecBot
PRESS-RELEASE ·Filed Mar 12, 2026

CRVS

Corvus Pharmaceuticals, Inc.
BULLISH
Impact 8/10
Horizonmonths Processed8mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▲ Bullish

Investors should monitor upcoming data readouts from the Phase 2 atopic dermatitis trial and the ongoing Phase 3 PTCL trial. The extended cash runway reduces near-term dilution risk and supports multiple value inflection points through 2027.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$15.32
T+0 close · Mar 12, 2026 · via day close
Latest settled
−27.22%
T+60 · $11.15
Vs SPY
−38.83%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 13 $15.32entry
  2. T+1 · 8mo ago +2.61%α +1.59% · $15.72
  3. T+5 · 8mo ago −12.99%α −10.87% · $13.33
  4. T+20 · 7mo ago −0.98%α −4.57% · $15.17
  5. T+60 · 5mo ago −27.22%α −38.83% · $11.15
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Corvus Pharmaceuticals reported financial results for Q4 and full year 2025, highlighted by positive Phase 1 atopic dermatitis trial data for soquelitinib, initiation of a Phase 2 trial in the same indication, and a successful $189 million public offering extending cash runway into Q2 2028. Despite increased R&D spending and a slight YoY increase in net loss, the company is advancing multiple clinical programs with upcoming data catalysts.

Key Financial Metrics

EPS
$-0.19
Deal Value
$189.4M

Key Facts

  • Positive Phase 1 data in atopic dermatitis: 75% of soquelitinib patients achieved EASI 75 vs. 20% placebo; no severe adverse events.
  • Initiated Phase 2 atopic dermatitis trial with ~200 patients; additional Phase 2 trials in asthma and hidradenitis suppurativa planned for 2026.
  • Completed public offering raising $189.4 million in net proceeds, extending cash runway into Q2 2028.
  • Cash, cash equivalents, and marketable securities: $56.8 million as of December 31, 2025 (excluding $189.4 million from January 2026 financing).
  • R&D expenses increased to $33.7 million in 2025 from $19.4 million in 2024 due to clinical and manufacturing costs.
  • Net loss for 2025 was $15.3 million vs. $62.3 million in 2024, a significant improvement despite higher operating costs.

Financial Impact

The $189.4 million financing significantly strengthens the balance sheet and funds operations into 2028. R&D spend increased 74% YoY to $33.7 million, reflecting accelerated development.

cashR&D expensenet lossdilution

Risk Factors

  • Clinical trial results may not replicate Phase 1 success, particularly in larger, more diverse populations.
  • The company remains pre-revenue with no near-term path to profitability; valuation is entirely dependent on clinical outcomes.
  • Dilution from the recent offering may pressure shares in the short term despite long-term runway benefits.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3255077

US Market Status

Market Closed · Opens in 6h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 12, 2026